OTCMKTS:APLIF Appili Therapeutics (APLIF) Stock Price, News & Analysis → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free APLIF Stock Alerts $0.03 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.02▼$0.0350-Day Range$0.02▼$0.0452-Week Range$0.02▼$0.08Volume87,134 shsAverage Volume266,875 shsMarket Capitalization$3.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsHeadlinesShort InterestStock AnalysisChartEarningsHeadlinesShort Interest Get Appili Therapeutics alerts: Email Address Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Appili Therapeutics Stock (OTCMKTS:APLIF)Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.Read More APLIF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APLIF Stock News HeadlinesApril 26, 2024 | finance.yahoo.comAppili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.April 26, 2024 | globenewswire.comAppili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 18, 2024 | finance.yahoo.comAppili Therapeutics Inc. (APLIF)April 4, 2024 | uk.investing.comAditxt to acquire Appili Therapeutics in strategic moveApril 2, 2024 | businesswire.comAditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)April 2, 2024 | finance.yahoo.comAppili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.April 2, 2024 | globenewswire.comAppili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.March 12, 2024 | globenewswire.comResearchers Publish Manuscript on the Prevention and Emergency Response to Tularemia OutbreaksFebruary 14, 2024 | finanznachrichten.deAppili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024February 14, 2024 | seekingalpha.comAppili Therapeutics reports Q3 resultsFebruary 13, 2024 | finance.yahoo.comAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024February 13, 2024 | globenewswire.comAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024February 3, 2024 | morningstar.comAppili Therapeutics Inc Ordinary SharesDecember 6, 2023 | finance.yahoo.comAPLIF: ATI-1701 Program Awarded Additional US$6.6 Million in Funding…November 14, 2023 | msn.comAppili Therapeutics GAAP EPS of -C$0.01November 13, 2023 | finance.yahoo.comAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024October 25, 2023 | finance.yahoo.comAppili Therapeutics’ Biodefense Vaccine Candidate ATI-1701 is Awarded Additional Funding from the U.S. Air Force AcademyOctober 5, 2023 | finance.yahoo.comAPLIF: FDA Approves LIKMEZ™ (ATI-1501)…September 27, 2023 | ca.finance.yahoo.comUPDATE 2-Canada's Appili gets US FDA approval for oral antibiotic solutionSeptember 27, 2023 | finance.yahoo.comAppili Therapeutics Presents at the 10th International Tularemia ConferenceSeptember 25, 2023 | marketwatch.comAppili Therapeutics' Licensing Partner Gets FDA Approval for Metronidazole Oral SuspensionSeptember 25, 2023 | stockhouse.comAppili Therapeutics Announces U.S. FDA Approval of LIKMEZ(TM) (ATI-1501) Metronidazole Oral SuspensionSeptember 25, 2023 | markets.businessinsider.comAppili Therapeutics Says FDA Approves LIKMEZ Metronidazole Oral SuspensionSeptember 25, 2023 | finance.yahoo.comAppili Therapeutics Announces U.S. FDA Approval of LIKMEZ™ (ATI-1501) Metronidazole Oral SuspensionSeptember 25, 2023 | finance.yahoo.comUPDATE 1-Canada's Appili gets US FDA approval for oral antibiotic solutionSee More Headlines Receive APLIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/13/2024Today4/26/2024Next Earnings (Estimated)6/21/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:APLIF CUSIPN/A CIKN/A Webwww.appilitherapeutics.com Phone902-442-4655FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,990,000.00 Net Margins-456.86% Pretax Margin-452.87% Return on EquityN/A Return on Assets-229.96% Debt Debt-to-Equity RatioN/A Current Ratio0.46 Quick Ratio0.46 Sales & Book Value Annual Sales$280,000.00 Price / Sales12.99 Cash FlowN/A Price / Cash FlowN/A Book Value($0.05) per share Price / Book-0.60Miscellaneous Outstanding Shares121,270,000Free Float106,908,000Market Cap$3.64 million OptionableNot Optionable Beta-0.30 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Donald D. Cilla Jr.M.B.A., Pharmd, CEO, President & DirectorMr. Kenneth G. HowlingChief Financial OfficerDr. Gary S. Nabors Ph.D.Chief Development OfficerKey CompetitorsRevelation BiosciencesNASDAQ:REVBPhaseBio PharmaceuticalsNASDAQ:PHASMateon TherapeuticsOTCMKTS:MATNPhio PharmaceuticalsNASDAQ:PHIOGeoVax LabsNASDAQ:GOVXView All Competitors APLIF Stock Analysis - Frequently Asked Questions How have APLIF shares performed in 2024? Appili Therapeutics' stock was trading at $0.0265 on January 1st, 2024. Since then, APLIF stock has increased by 13.2% and is now trading at $0.03. View the best growth stocks for 2024 here. Are investors shorting Appili Therapeutics? Appili Therapeutics saw a drop in short interest in the month of April. As of April 15th, there was short interest totaling 37,400 shares, a drop of 69.9% from the March 31st total of 124,200 shares. Based on an average daily trading volume, of 1,614,600 shares, the days-to-cover ratio is currently 0.0 days. View Appili Therapeutics' Short Interest. When is Appili Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, June 21st 2024. View our APLIF earnings forecast. How were Appili Therapeutics' earnings last quarter? Appili Therapeutics Inc. (OTCMKTS:APLIF) issued its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.01). The company earned $0.36 million during the quarter. How do I buy shares of Appili Therapeutics? Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:APLIF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Appili Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
